Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed

Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.S. government trial. That study showed a trend toward better survival for remdesivir but the difference was not statistically significant.

from Moneycontrol World News https://bit.ly/3fmAY9Y